title: The role of aberrant promoter hypermethylation of DACT1 in bladder urothelial carcinoma.
abstract: The purpose of this study was to determine the relationship between hypermethylation of DACT1 gene promoter and lower mRNA expression in bladder urothelial carcinoma tissue. The methylation status of 29 urothelial carcinoma samples and 29 normal tissue samples were examined by methylation-specific polymerase chain reaction (MSP). The DACT1 mRNA transcript levels and DACT1 protein levels in all samples were then evaluated to define the relationship between the methylation status of the DACT1 promoter and its expression at the transcriptional and translational levels. Decreased expression of DACT1 was detected in 89.66% of urothelial carcinomas (26/29; P < 0.005). Promoter hypermethylation was found in 58.62% (17/29) urothelial carcinomas and 25% (7/29) normal tissues, respectively (P < 0.05). DACT1 expression was lower in tissues where the DACT1 gene promoter was hypermethylated than in unmethylated tissues (0.25±0.17 vs 0.69±0.30, P < 0.05). DACT1 gene hypermethylation was closely related to tumor size, grade and stage (P < 0.05). Our results indicate that silencing and downregulation of DACT1 mRNA may be implicated in carcinogenesis and the progression of bladder urothelial carcinoma, and may be a potential prognostic factor.
authors.affiliation: Department of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
authors.forename: Huan
authors.initials: H
authors.lastname: Cheng
authors.forename: Zhonglei
authors.initials: Z
authors.lastname: Deng
authors.forename: Zengjun
authors.initials: Z
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Jiantang
authors.initials: J
authors.lastname: Su
keywords: DACT1; DNA methylation; bladder urothelial carcinoma; hypermethylation
references.citation: Cell. 1997 Feb 7;88(3):333-46
references.pmid: 9039260
references.citation: J Biol Chem. 2004 Jul 23;279(30):31735-44
references.pmid: 15150277
references.citation: Cancer Res. 2010 Oct 15;70(20):8015-24
references.pmid: 20736368
references.citation: Cell. 1988 Apr 22;53(2):173-4
references.pmid: 3282673
references.citation: Int J Cancer. 1999 Mar 15;80(6):827-41
references.pmid: 10074914
references.citation: Urol Oncol. 2008 Sep-Oct;26(5):465-9
references.pmid: 18640857
references.citation: Cell. 2007 Feb 23;128(4):683-92
references.pmid: 17320506
references.citation: J Neurosci. 2010 Mar 24;30(12):4362-8
references.pmid: 20335472
references.citation: Zhonghua Yi Xue Za Zhi. 2004 Feb 17;84(4):290-3
references.pmid: 15059510
references.citation: Carcinogenesis. 2009 Feb;30(2):214-21
references.pmid: 19037089
references.citation: Wiley Interdiscip Rev Syst Biol Med. 2010 Nov-Dec;2(6):654-69
references.pmid: 20890963
references.citation: Curr Top Microbiol Immunol. 2000;249:101-18
references.pmid: 10802941
references.citation: Am J Pathol. 2010 Jul;177(1):21-8
references.pmid: 20489138
references.citation: Cancer Res. 2006 Jan 1;66(1):267-82
references.pmid: 16397240
references.citation: Cancer Sci. 2010 Jan;101(1):36-45
references.pmid: 19891661
references.citation: Curr Opin Oncol. 2011 Jan;23(1):69-76
references.pmid: 21119515
references.citation: Int J Cancer. 2006 Dec 1;119(11):2603-6
references.pmid: 16991125
references.citation: J Natl Cancer Inst. 2005 Oct 19;97(20):1548; author reply 1548-9
references.pmid: 16234569
references.citation: BMC Med Genomics. 2011 May 20;4:45
references.pmid: 21599969
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1657-64
references.pmid: 21680534
references.citation: Mol Carcinog. 2011 Feb;50(2):89-99
references.pmid: 21229606
references.citation: Am J Physiol Renal Physiol. 2010 Oct;299(4):F740-51
references.pmid: 20685821
references.citation: J Urol. 2010 Aug;184(2):731-7
references.pmid: 20639048
references.citation: Genes Dev. 2000 Aug 1;14(15):1837-51
references.pmid: 10921899